<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25692777</PMID><DateCompleted><Year>2015</Year><Month>11</Month><Day>11</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>2</Issue><PubDate><Year>2015</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>Resveratrol inhibits enterovirus 71 replication and pro-inflammatory cytokine secretion in rhabdosarcoma cells through blocking IKKs/NF-&#x3ba;B signaling pathway.</ArticleTitle><Pagination><StartPage>e0116879</StartPage><MedlinePgn>e0116879</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e0116879</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0116879</ELocationID><Abstract><AbstractText>Polydatin and resveratrol, as major active components in Polygonum cuspidatum, have anti-inflammatory, antioxidant and antitumor functions. However, the effect and mechanism of polydatin and resveratrol on enterovirus 71 (EV71) have not been reported. In this study, resveratrol revealed strong antiviral activity on EV71, while polydatin had weak effect. Neither polydatin nor resveratrol exhibited influence on viral attachment. Resveratrol could effectively inhibit the synthesis of EV71/VP1 and the phosphorylation of IKK&#x3b1;, IKK&#x3b2;, IKK&#x3b3;, IKB&#x3b1;, NF-&#x3ba;B p50 and NF-&#x3ba;B p65, respectively. Meanwhile, the remarkably increased secretion of IL-6 and TNF-&#x3b1; in EV71-infected rhabdosarcoma (RD) cells could be blocked by resveratrol. These results demonstrated that resveratrol inhibited EV71 replication and cytokine secretion in EV71-infected RD cells through blocking IKKs/NF-&#x3ba;B signaling pathway. Thus, resveratrol may have potent antiviral effect on EV71 infection.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Li</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Clinical Laboratory, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu 213003, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yuanyuan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Clinical Laboratory, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu 213003, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gu</LastName><ForeName>Zhiwen</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Clinical Laboratory, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu 213003, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yuyue</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Clinical Laboratory, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu 213003, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Mei</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Clinical Laboratory, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu 213003, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ji</LastName><ForeName>Yun</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Clinical Laboratory, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu 213003, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Jing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Clinical Laboratory, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu 213003, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Xiaopeng</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Clinical Laboratory, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu 213003, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Lirong</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Clinical Laboratory, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu 213003, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Jingtin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Oncology Laboratory, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu 213003, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Weifeng</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Clinical Laboratory, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu 213003, P. R. China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>02</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005960">Glucosides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016328">NF-kappa B</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013267">Stilbenes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.10</RegistryNumber><NameOfSubstance UI="D051550">I-kappa B Kinase</NameOfSubstance></Chemical><Chemical><RegistryNumber>Q369O8926L</RegistryNumber><NameOfSubstance UI="D000077185">Resveratrol</NameOfSubstance></Chemical><Chemical><RegistryNumber>XM261C37CQ</RegistryNumber><NameOfSubstance UI="C058229">polydatin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005960" MajorTopicYN="N">Glucosides</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051550" MajorTopicYN="N">I-kappa B Kinase</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016328" MajorTopicYN="N">NF-kappa B</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077185" MajorTopicYN="N">Resveratrol</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012208" MajorTopicYN="N">Rhabdomyosarcoma</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013267" MajorTopicYN="N">Stilbenes</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing Interests: </b>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>8</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>12</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>2</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>2</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>11</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>2</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25692777</ArticleId><ArticleId IdType="pmc">PMC4333343</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0116879</ArticleId><ArticleId IdType="pii">PONE-D-14-37112</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hsu CH, Lu CY, Shao PL, Lee PI, Kao CL, et al. (2011) Epidemiologic and clinical features of non-polio enteroviral infections in northern Taiwan in 2008. J Microbiol Immunol Infect 44:265&#x2013;273. 10.1016/j.jmii.2011.01.029</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmii.2011.01.029</ArticleId><ArticleId IdType="pubmed">21524954</ArticleId></ArticleIdList></Reference><Reference><Citation>Irani DN (2008) Aseptic meningitis and viral myelitis. Neurol Clin 26:635&#x2013;655. 10.1016/j.ncl.2008.03.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ncl.2008.03.003</ArticleId><ArticleId IdType="pmc">PMC2728900</ArticleId><ArticleId IdType="pubmed">18657719</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu KX, Ng MM-L, Chu JJ (2010) Developments towards antiviral therapies against enterovirus 71. Drug Discov Today 15:1041&#x2013;1051. 10.1016/j.drudis.2010.10.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.drudis.2010.10.008</ArticleId><ArticleId IdType="pmc">PMC7108380</ArticleId><ArticleId IdType="pubmed">20974282</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghanim H, Sia CL, Korzeniewski K, Lohano T, Abuaysheh S, et al. (2011) A resveratrol and polyphenol preparation suppresses oxidative and inflammatory stress response to a high-fat, high-carbohydrate meal. J Clin Endocrinol Metab 96:1409&#x2013;1414. 10.1210/jc.2010-1812</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/jc.2010-1812</ArticleId><ArticleId IdType="pmc">PMC3085195</ArticleId><ArticleId IdType="pubmed">21289251</ArticleId></ArticleIdList></Reference><Reference><Citation>Clouser CL, Chauhan J, Bess MA, van Oploo JL, Zhou D, et al. (2012) Anti-HIV-1 activity of resveratrol derivatives and synergistic inhibition of HIV-1 by the combination of resveratrol and decitabine. Bioorg Med Chem Lett 22:6642&#x2013;6646. 10.1016/j.bmcl.2012.08.108</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bmcl.2012.08.108</ArticleId><ArticleId IdType="pmc">PMC3482103</ArticleId><ArticleId IdType="pubmed">23010273</ArticleId></ArticleIdList></Reference><Reference><Citation>Faith SA, Sweet TJ, Bailey E, Booth T, Docherty JJ (2006) Resveratrol suppresses nuclear factor-kappaB in herpes simplex virus infected cells. Antiviral Res 72:242&#x2013;251.</Citation><ArticleIdList><ArticleId IdType="pubmed">16876885</ArticleId></ArticleIdList></Reference><Reference><Citation>Docherty JJ, Sweet TJ, Bailey E, Faith SA, Booth T (2006) Resveratrol inhibition of varicella-zoster virus replication in vitro. Antiviral Res 72:171&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pubmed">16899306</ArticleId></ArticleIdList></Reference><Reference><Citation>Evers DL, Wang X, Huong SM, Huang DY, Huang ES (2004) 3,4',5-Trihydroxy-trans-stilbene (resveratrol) inhibits human cytomegalovirus replication and virus-induced cellular signaling. Antiviral Res 63:85&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">15302137</ArticleId></ArticleIdList></Reference><Reference><Citation>Du QH, Peng C, Zhang H (2013) Polydatin: a review of pharmacology and pharmacokinetics. Pharm Biol 51:1347&#x2013;1354. 10.3109/13880209.2013.792849</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/13880209.2013.792849</ArticleId><ArticleId IdType="pubmed">23862567</ArticleId></ArticleIdList></Reference><Reference><Citation>De Maria S, Scognamiglio I, Lombardi A, Amodio N, Caraglia M, et al. (2013) Polydatin, a natural precursor of resveratrol, induces cell cycle arrest and differentiation of human colorectal Caco-2 cell. J Transl Med 11:264 10.1186/1479-5876-11-264</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1479-5876-11-264</ArticleId><ArticleId IdType="pmc">PMC3854516</ArticleId><ArticleId IdType="pubmed">24138806</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L, Lan Z, Lin Q, Mi X, He Y, et al. (2013) Polydatin ameliorates renal injury by attenuating oxidative stress-related inflammatory responses in fructose-induced urate nephropathic mice. Food Chem Toxicol 52:28&#x2013;35. 10.1016/j.fct.2012.10.037</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.fct.2012.10.037</ArticleId><ArticleId IdType="pubmed">23137955</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravagnan G, De Filippis A, Carteni M, De Maria S, Cozza V, et al. (2013) Polydatin, a natural precursor of resveratrol, induces beta-defensin production and reduces inflammatory response. Inflammation 36:26&#x2013;34. 10.1007/s10753-012-9516-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10753-012-9516-8</ArticleId><ArticleId IdType="pubmed">22956122</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng Y, Zhang HT, Sun L, Guo S, Ouyang S, et al. (2006) Involvement of cell adhesion molecules in polydatin protection of brain tissues from ischemia-reperfusion injury. Brain Res 1110:193&#x2013;200.</Citation><ArticleIdList><ArticleId IdType="pubmed">16870162</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng YH, Alex D, Huang HQ, Wang N, Yu N, et al. (2011) Inhibition of TNF-alpha-mediated endothelial cell-monocyte cell adhesion and adhesion molecules expression by the resveratrol derivative, trans-3,5,4'-trimethoxystilbene. Phytother Res 25:451&#x2013;457. 10.1002/ptr.3279</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ptr.3279</ArticleId><ArticleId IdType="pubmed">20740479</ArticleId></ArticleIdList></Reference><Reference><Citation>Heldt CL, Hernandez R, Mudiganti U, Gurgel PV, Brown DT, et al. (2006) A colorimetric assay for viral agents that produce cytopathic effects. J Virol Methods 135:56&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">16516983</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo JP, Pang J, Wang XW, Shen ZQ, Jin M, et al. (2006) In vitro screening of traditionally used medicinal plants in China against enteroviruses. World J Gastroenterol 12:4078&#x2013;4081.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4087726</ArticleId><ArticleId IdType="pubmed">16810764</ArticleId></ArticleIdList></Reference><Reference><Citation>Mankan AK, Lawless MW, Gray SG, Kelleher D, McManus R (2009) NF-kappaB regulation: the nuclear response. J Cell Mol Med 13:631&#x2013;643. 10.1111/j.1582-4934.2009.00632.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1582-4934.2009.00632.x</ArticleId><ArticleId IdType="pmc">PMC3822870</ArticleId><ArticleId IdType="pubmed">19438970</ArticleId></ArticleIdList></Reference><Reference><Citation>Tung WH, Hsieh HL, Lee IT, Yang CM (2011) Enterovirus 71 modulates a COX-2/PGE2/cAMP-dependent viral replication in human neuroblastoma cells: role of the c-Src/EGFR/p42/p44 MAPK/CREB signaling pathway. J Cell Biochem 112:559&#x2013;570. 10.1002/jcb.22946</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcb.22946</ArticleId><ArticleId IdType="pmc">PMC7166325</ArticleId><ArticleId IdType="pubmed">21268077</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar N, Xin ZT, Liang Y, Ly H (2008) NF-kappaB signaling differentially regulates influenza virus RNA synthesis. J Virol 82:9880&#x2013;9889. 10.1128/JVI.00909-08</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00909-08</ArticleId><ArticleId IdType="pmc">PMC2566266</ArticleId><ArticleId IdType="pubmed">18701591</ArticleId></ArticleIdList></Reference><Reference><Citation>La Frazia S, Amici C, Santoro MG (2006) Antiviral activity of proteasome inhibitors in herpes simplex virus-1 infection: role of nuclear factor-kappaB. Antivir Ther 11:995&#x2013;1004.</Citation><ArticleIdList><ArticleId IdType="pubmed">17302369</ArticleId></ArticleIdList></Reference><Reference><Citation>Klebl BM, Kurtenbach A, Salassidis K, Daub H, Herget T (2005) Host cell targets in HCV therapy: novel strategy or proven practice? Antivir Chem Chemother 16:69&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">15889531</ArticleId></ArticleIdList></Reference><Reference><Citation>Rawlinson SM, Pryor MJ, Wright PJ, Jans DA (2006) Dengue virus RNA polymerase NS5: a potential therapeutic target? Curr Drug Targets 7:1623&#x2013;1638.</Citation><ArticleIdList><ArticleId IdType="pubmed">17168837</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Q, Weber E, Yang H (2013) Drug targets for rational design against emerging coronaviruses. Infect Disord Drug Targets 13:116&#x2013;127.</Citation><ArticleIdList><ArticleId IdType="pubmed">23895136</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin TY, Liu YC, Jheng JR, Tsai HP, Jan JT, et al. (2009) Anti-enterovirus 71 activity screening of chinese herbs with anti-infection and inflammation activities. Am J Chin Med 37:143&#x2013;158.</Citation><ArticleIdList><ArticleId IdType="pubmed">19222118</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X, Liu Y, Hou X, Peng H, Zhang L, et al. (2013) Chlorogenic acid inhibits the replication and viability of enterovirus 71 in vitro. PLoS One 8:e76007 10.1371/journal.pone.0076007</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0076007</ArticleId><ArticleId IdType="pmc">PMC3786884</ArticleId><ArticleId IdType="pubmed">24098754</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X, Wang C, Xu L, Wang W, Yang G, et al. (2013) A laboratory evaluation of medicinal herbs used in china for the treatment of hand, foot, and mouth disease. Evid Based Complement Alternat Med 2013:504563 10.1155/2013/504563</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2013/504563</ArticleId><ArticleId IdType="pmc">PMC3608275</ArticleId><ArticleId IdType="pubmed">23554831</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu X, Sun A, Liu R (2005) Preparative isolation and purification of five compounds from the Chinese medicinal herb Polygonum cuspidatum Sieb. et Zucc by high-speed counter-current chromatography. J Chromatogr A 1097:33&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">16298183</ArticleId></ArticleIdList></Reference><Reference><Citation>Carrizzo A, Forte M, Damato A, Trimarco V, Salzano F, et al. (2013) Antioxidant effects of resveratrol in cardiovascular, cerebral and metabolic diseases. Food Chem Toxicol 61:215&#x2013;226. 10.1016/j.fct.2013.07.021</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.fct.2013.07.021</ArticleId><ArticleId IdType="pubmed">23872128</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaminski BM, Weigert A, Scherzberg MC, Ley S, Gilbert B, et al. (2014) Resveratrol-induced potentiation of the antitumor effects of oxaliplatin is accompanied by an altered cytokine profile of human monocyte-derived macrophages. Apoptosis.</Citation><ArticleIdList><ArticleId IdType="pubmed">24715262</ArticleId></ArticleIdList></Reference><Reference><Citation>Augustine N, Goel AK, Sivakumar KC, Ajay Kumar R, Thomas S (2014) Resveratrol&#x2014;A potential inhibitor of biofilm formation in Vibrio cholerae. Phytomedicine 21:286&#x2013;289. 10.1016/j.phymed.2013.09.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phymed.2013.09.010</ArticleId><ArticleId IdType="pubmed">24182988</ArticleId></ArticleIdList></Reference><Reference><Citation>Campagna M, Rivas C (2010) Antiviral activity of resveratrol. Biochem Soc Trans 38:50&#x2013;53. 10.1042/BST0380050</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BST0380050</ArticleId><ArticleId IdType="pubmed">20074034</ArticleId></ArticleIdList></Reference><Reference><Citation>Docherty JJ, Fu MM, Stiffler BS, Limperos RJ, Pokabla CM, et al. (1999) Resveratrol inhibition of herpes simplex virus replication. Antiviral Res 43:145&#x2013;155.</Citation><ArticleIdList><ArticleId IdType="pubmed">10551373</ArticleId></ArticleIdList></Reference><Reference><Citation>Heredia A, Davis C, Amin MN, Le NM, Wainberg MA, et al. (2014) Targeting host nucleotide biosynthesis with resveratrol inhibits emtricitabine-resistant HIV-1. AIDS 28:317&#x2013;323. 10.1097/QAD.0000000000000168</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/QAD.0000000000000168</ArticleId><ArticleId IdType="pmc">PMC4469130</ArticleId><ArticleId IdType="pubmed">24326355</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin HC, Chen YF, Hsu WH, Yang CW, Kao CH, et al. (2012) Resveratrol helps recovery from fatty liver and protects against hepatocellular carcinoma induced by hepatitis B virus X protein in a mouse model. Cancer Prev Res (Phila) 5:952&#x2013;962. 10.1158/1940-6207.CAPR-12-0001</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1940-6207.CAPR-12-0001</ArticleId><ArticleId IdType="pubmed">22659145</ArticleId></ArticleIdList></Reference><Reference><Citation>De Leo A, Arena G, Lacanna E, Oliviero G, Colavita F, et al. (2012) Resveratrol inhibits Epstein Barr Virus lytic cycle in Burkitt's lymphoma cells by affecting multiple molecular targets. Antiviral Res 96:196&#x2013;202. 10.1016/j.antiviral.2012.09.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2012.09.003</ArticleId><ArticleId IdType="pubmed">22985630</ArticleId></ArticleIdList></Reference><Reference><Citation>Palamara AT, Nencioni L, Aquilano K, De Chiara G, Hernandez L, et al. (2005) Inhibition of influenza A virus replication by resveratrol. J Infect Dis 191:1719&#x2013;1729.</Citation><ArticleIdList><ArticleId IdType="pubmed">15838800</ArticleId></ArticleIdList></Reference><Reference><Citation>Rivas-Aravena A, Vallejos-Vidal E, Cortez-San Martin M, Reyes-Lopez F, Tello M, et al. (2011) Inhibitory effect of a nucleotide analog on infectious salmon anemia virus infection. J Virol 85:8037&#x2013;8045. 10.1128/JVI.00533-11</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00533-11</ArticleId><ArticleId IdType="pmc">PMC3147947</ArticleId><ArticleId IdType="pubmed">21653663</ArticleId></ArticleIdList></Reference><Reference><Citation>Bougie I, Bisaillon M (2004) The broad spectrum antiviral nucleoside ribavirin as a substrate for a viral RNA capping enzyme. J Biol Chem 279:22124&#x2013;22130.</Citation><ArticleIdList><ArticleId IdType="pubmed">15037606</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji H, Zhang X, Du Y, Liu H, Li S, et al. (2012) Polydatin modulates inflammation by decreasing NF-kappaB activation and oxidative stress by increasing Gli1, Ptch1, SOD1 expression and ameliorates blood-brain barrier permeability for its neuroprotective effect in pMCAO rat brain. Brain Res Bull 87:50&#x2013;59. 10.1016/j.brainresbull.2011.09.021</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainresbull.2011.09.021</ArticleId><ArticleId IdType="pubmed">22001340</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui S, Wang J, Fan T, Qin B, Guo L, et al. (2011) Crystal structure of human enterovirus 71 3C protease. J Mol Biol 408:449&#x2013;461. 10.1016/j.jmb.2011.03.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmb.2011.03.007</ArticleId><ArticleId IdType="pmc">PMC7094522</ArticleId><ArticleId IdType="pubmed">21396941</ArticleId></ArticleIdList></Reference><Reference><Citation>Han JF, Cao RY, Tian X, Yu M, Qin ED, et al. (2010) Producing infectious enterovirus type 71 in a rapid strategy. Virol J 7:116 10.1186/1743-422X-7-116</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-422X-7-116</ArticleId><ArticleId IdType="pmc">PMC2892457</ArticleId><ArticleId IdType="pubmed">20525351</ArticleId></ArticleIdList></Reference><Reference><Citation>Shang L, Xu M, Yin Z (2013) Antiviral drug discovery for the treatment of enterovirus 71 infections. Antiviral Res 97:183&#x2013;194. 10.1016/j.antiviral.2012.12.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2012.12.005</ArticleId><ArticleId IdType="pubmed">23261847</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanzilli G, Cottarelli A, Nicotera G, Guida S, Ravagnan G, et al. (2012) Anti-inflammatory effect of resveratrol and polydatin by in vitro IL-17 modulation. Inflammation 35:240&#x2013;248. 10.1007/s10753-011-9310-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10753-011-9310-z</ArticleId><ArticleId IdType="pubmed">21369944</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo R, Li W, Liu B, Li S, Zhang B, et al. (2014) Resveratrol protects vascular smooth muscle cells against high glucose-induced oxidative stress and cell proliferation in vitro. Med Sci Monit Basic Res 20:82&#x2013;92. 10.12659/MSMBR.890858</Citation><ArticleIdList><ArticleId IdType="doi">10.12659/MSMBR.890858</ArticleId><ArticleId IdType="pmc">PMC4095779</ArticleId><ArticleId IdType="pubmed">24971582</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu H, Ren J, Chen H, Huang Y, Li H, et al. (2014) Resveratrol Protects against Cigarette Smoke-Induced Oxidative Damage and Pulmonary Inflammation. J Biochem Mol Toxicol.</Citation><ArticleIdList><ArticleId IdType="pubmed">24957013</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang HS, Zhou Y, Wu MR, Zhou HS, Xu F (2009) Resveratrol inhibited Tat-induced HIV-1 LTR transactivation via NAD(+)-dependent SIRT1 activity. Life Sci 85:484&#x2013;489. 10.1016/j.lfs.2009.07.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2009.07.014</ArticleId><ArticleId IdType="pubmed">19664641</ArticleId></ArticleIdList></Reference><Reference><Citation>De Leo A, Arena G, Stecca C, Raciti M, Mattia E (2011) Resveratrol inhibits proliferation and survival of Epstein Barr virus-infected Burkitt's lymphoma cells depending on viral latency program. Mol Cancer Res 9:1346&#x2013;1355. 10.1158/1541-7786.MCR-11-0145</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1541-7786.MCR-11-0145</ArticleId><ArticleId IdType="pubmed">21856773</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang G, Zhou F, Gu B, Ding C, Feng D, et al. (2012) In vitro and in vivo evaluation of ribavirin and pleconaril antiviral activity against enterovirus 71 infection. Arch Virol 157:669&#x2013;679. 10.1007/s00705-011-1222-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00705-011-1222-6</ArticleId><ArticleId IdType="pubmed">22245989</ArticleId></ArticleIdList></Reference><Reference><Citation>Li ZH, Li CM, Ling P, Shen FH, Chen SH, et al. (2008) Ribavirin reduces mortality in enterovirus 71-infected mice by decreasing viral replication. J Infect Dis 197:854&#x2013;857. 10.1086/527326</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/527326</ArticleId><ArticleId IdType="pmc">PMC7109938</ArticleId><ArticleId IdType="pubmed">18279075</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Song Z, Qin B, Chen L, Hu Y, et al. (2013) Rupintrivir is a promising candidate for treating severe cases of enterovirus-71 infection: evaluation of antiviral efficacy in a murine infection model. Antiviral Res 97:264&#x2013;269. 10.1016/j.antiviral.2012.12.029</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2012.12.029</ArticleId><ArticleId IdType="pubmed">23295352</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>